OptiNose, Inc. (OPTN)

NASDAQ: OPTN · IEX Real-Time Price · USD
1.690
+0.040 (2.42%)
At close: Feb 27, 2024, 4:00 PM
1.770
+0.080 (4.73%)
After-hours: Feb 27, 2024, 7:59 PM EST
2.42%
Market Cap 185.31M
Revenue (ttm) 71.98M
Net Income (ttm) -40.72M
Shares Out 112.31M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 554,950
Open 1.690
Previous Close 1.650
Day's Range 1.600 - 1.750
52-Week Range 0.900 - 2.070
Beta -0.29
Analysts Strong Buy
Price Target 3.00 (+77.52%)
Earnings Date Mar 12, 2024

About OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. OptiNose, ... [Read more]

Sector Healthcare
IPO Date Oct 13, 2017
Employees 141
Stock Exchange NASDAQ
Ticker Symbol OPTN
Full Company Profile

Financial Performance

In 2022, OptiNose's revenue was $76.28 million, an increase of 2.18% compared to the previous year's $74.65 million. Losses were -$74.83 million, -9.07% less than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for OPTN stock is "Strong Buy." The 12-month stock price forecast is $3.0, which is an increase of 77.52% from the latest price.

Price Target
$3.0
(77.52% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 Clinical Trials (ReOpen1 and ReO...

5 weeks ago - GlobeNewsWire

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis

2 months ago - GlobeNewsWire

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

3 months ago - GlobeNewsWire

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance

3 months ago - GlobeNewsWire

Optinose to Present at the 2023 Cantor Global Healthcare Conference

YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced tha...

5 months ago - GlobeNewsWire

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance

7 months ago - GlobeNewsWire

Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million

Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE net revenue guidance on August 10 YARDLEY, Pa.

7 months ago - GlobeNewsWire

Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

YARDLEY, Pa., June 16, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announce...

9 months ago - GlobeNewsWire

Optinose to Present at the Jefferies Healthcare Conference

YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

9 months ago - GlobeNewsWire

Optinose Reports First Quarter 2023 Financial Results and Operational Updates

Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis

10 months ago - GlobeNewsWire

Optinose Announces Reporting Date for First Quarter 2023 Financial Results

Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time

10 months ago - GlobeNewsWire

Optinose to Present at the Needham Virtual Healthcare Conference

YARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced tha...

11 months ago - GlobeNewsWire

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million

1 year ago - GlobeNewsWire

Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results

Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time

1 year ago - GlobeNewsWire

Optinose Announces CEO Transition and Business Update

Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors

1 year ago - GlobeNewsWire

Optinose Appoints Paul Spence as Chief Commercial Officer

YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...

1 year ago - GlobeNewsWire

Optinose Announces Departure of Acting Chief Financial Officer

YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

1 year ago - GlobeNewsWire

Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference

$50 Million from Recent Financing Extends Expected Cash Runway Beyond the Expected PDUFA Action Date for XHANCE as a Treatment for Chronic Sinusitis

1 year ago - GlobeNewsWire

Optinose Announces Pricing of Public Offering of Common Stock and Warrants

YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...

1 year ago - GlobeNewsWire

Optinose Announces Proposed Public Offering of Common Stock and Warrants

YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

1 year ago - GlobeNewsWire

Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting

YARDLEY, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

1 year ago - GlobeNewsWire

Optinose Announces Reporting Date for Third Quarter 2022 Financial Results

Conference Call and Webcast to be held November 10, 2022, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held November 10, 2022, at 8:00 a.m. Eastern Time

1 year ago - GlobeNewsWire

Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022

Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used XHANCE in landmark ReOpen phase 3 clinical trial program

1 year ago - GlobeNewsWire

Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting

ReOpen1 Phase 3 Clinical Trial Chosen as a Top-Rated Abstract in Clinical Rhinology ReOpen1 Phase 3 Clinical Trial Chosen as a Top-Rated Abstract in Clinical Rhinology

1 year ago - GlobeNewsWire

Optinose Reports Second Quarter 2022 Financial Results and Operational Updates

Company reports second quarter XHANCE net revenue of $20.6 million increased 12%

1 year ago - GlobeNewsWire